EOLS - エボラス (Evolus Inc.) エボラス

 EOLSのチャート


 EOLSの企業情報

symbol EOLS
会社名 Evolus Inc (エボラス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エヴォルス(Evolus Inc.)は医療美容会社である。同社は医師および美容処置・治療法を提供することに重点を置く。また、自費の美容市場を提供することに焦点を当てる。製品候補であるPrabotulinumtoxinA(DWP-450)は大規模かつ成長的美容市場のニーズに対応する注入可能な900キロダルトンのボツリヌス毒素タイプである。同社は医師と患者にDWP-450による提案を提供する。OnabotulinumtoxinA(BOTOX)は米国にある神経毒素認可900kDaボツリヌス毒素A型複合体である。   エボラスは米国の医療審美企業。医師および患者に審美・美容手術や治療法での広範な選択肢を提供する。また、自己負担における医療市場に注力する。主な候補薬には、市場でニ―ズの高い900キロダルトン分子形態のA型ボツリヌス毒素注射剤「DWP-450」などがある。本社所在地はカリフォルニア州ア―バイン。   Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.
本社所在地 17901 Von Karman Avenue Suite 150 Irvine CA 92614 USA
代表者氏名 Vikram Malik ヴィクラム・マリク
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 949-284-4555
設立年月日 41214
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.evolus.com
nasdaq_url https://www.nasdaq.com/symbol/eols
adr_tso
EBITDA EBITDA(百万ドル) -18.51500
終値(lastsale) 16.43
時価総額(marketcap) 438270102.13
時価総額 時価総額(百万ドル) 438.27010
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 411.15510
当期純利益 当期純利益(百万ドル) -17.56000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Evolus Inc revenues was not reported. Net loss increased from $6.3M to $22.6M. Higher net loss reflects Revaluation of contingent royalty obliga increase from $0K to $9.1M (expense) General and Administrative - Balancing v increase from $1.8M to $6.8M (expense) Stock-based Compensation in SGA increase from $232K to $2.9M (expense).

 EOLSのテクニカル分析


 EOLSのニュース

   How Evolus Inc. (NASDAQ: EOLS) Could Be A Loss Maker Since It Is Up 96.31% YTD?  2022/06/25 14:30:00 Marketing Sentinel
During the last session, Evolus Inc. (NASDAQ:EOLS)’s traded shares were 0.76 million, with the beta value of the company hitting 2.04. At the end of the trading day, the stock’s price was $12.78, reflecting an intraday gain of 5.10% or $0.62. The 52-week high for the EOLS share is $14.34, that puts it down -12.21 … How Evolus Inc. (NASDAQ: EOLS) Could Be A Loss Maker Since It Is Up 96.31% YTD? Read More »
   Needham Is Bullish On This Botox Equivalent Aesthetics Company  2022/06/24 17:35:19 Benzinga
Needham initiated coverage on Evolus Inc (NASDAQ: EOLS ) with a price target of $18.00 (43% upside) and a Buy rating. Evolus is a pure-play aesthetics company focused on growing the presence of Jeuveau, its new neurotoxin product, in the approximately $3 billion global wrinkle treatment market. Jeuveau is a prescription medicine injected into muscles to improve the look of moderate to severe … Full story available on Benzinga.com
   Evolus attracts buy rating from Needham at $18 price target (NASDAQ:EOLS)  2022/06/23 15:10:45 Seeking Alpha
Evolus (EOLS) shares are up 5.3% in early trading on Wednesday after Needham started off coverage on this medical aesthetic company with a Buy Rating. Analyst Serge Belanger has set a…
   Evolus Inc. (EOLS): Is It Worth A Small Bite At $11.55?  2022/06/18 15:30:00 Stocks Register
Evolus Inc. (NASDAQ:EOLS) price on Friday, June 17, rose 0.79% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $11.55. A look at the stock’s price movement, the close in the last trading session was $11.46, moving within a range at $11.385 and $11.755. The beta value (5-Year … Evolus Inc. (EOLS): Is It Worth A Small Bite At $11.55? Read More »
   Evolus Inc. (NASDAQ: EOLS) Rose 61.08% From Its 52-Week Low; YTD Numbers Rose 99.69% – Here Are Some Things To Keep In Mind  2022/06/04 11:00:00 Marketing Sentinel
During the last session, Evolus Inc. (NASDAQ:EOLS)’s traded shares were 0.51 million, with the beta value of the company hitting 2.04. At the end of the trading day, the stock’s price was $13.00, reflecting an intraday loss of -4.90% or -$0.67. The 52-week high for the EOLS share is $14.34, that puts it down -10.31 … Evolus Inc. (NASDAQ: EOLS) Rose 61.08% From Its 52-Week Low; YTD Numbers Rose 99.69% – Here Are Some Things To Keep In Mind Read More »
   Evolus'' request to market anti-wrinkle therapy accepted in Australia  2022/02/08 14:40:51 Seeking Alpha
Evolus <> announced on Tuesday that the Australian Therapeutics Good Administration ((TGA)) accepted its submission seeking the regulatory approval of Nuceiva
   Evolus on the rise after Truist upgraded on prospects for wrinkles treatment  2022/01/20 18:13:32 Seeking Alpha
Evolus <> has recorded the biggest intraday gain in more than three months after Truist upgraded the Pharma company to Buy from Hold, citing its performance in the Jeuveau launch
   Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of Hold from Brokerages  2021/12/22 16:36:42 Transcript Daily
Evolus, Inc. (NASDAQ:EOLS) has received a consensus rating of Hold from the nine research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average 12 month price []
   Given A -179.42% Drop From High, Can Evolus Inc. (NASDAQ: EOLS) Quickly Recover?  2021/12/18 21:00:00 Marketing Sentinel
During the last session, Evolus Inc. (NASDAQ:EOLS)s traded shares were 0.59 million, with the beta value of the company hitting 2.36. At the end of the trading day, the stocks price was $6.22, reflecting an intraday gain of 6.69% or $0.39. The 52-week high for the EOLS share is $17.38, that puts it down -179.42 Given A -179.42% Drop From High, Can Evolus Inc. (NASDAQ: EOLS) Quickly Recover? Read More »
   Flowchart And Diagramming Tools Market Size, Landscape, Industry Analysis, Business Outlook, Current and Future Growth By 2028 | Microsoft, Zingtree, Nevron Software, EDrawSoft, Gliffy, Cinergix, NCH Software, Evolus, Visual Paradigm and REF Electronics.  2021/12/15 04:37:01 OpenPR
New Jersey, United States,- Verified Market Research has recently published a research report titled, Flowchart And Diagramming Tools Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used
   Global Online Flowchart Software Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027  2021/05/20 18:30:00 Ken Research
The global Online Flowchart Software market is expected to reach USD XX Million by 2027, with a CAGR of XX% from 2020 to 2027, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America). By Market Verdors: Visio Nulab Jgraph MyDraw EDrawSoft Gliffy Cinergix Omni Group Slickplan The Dia Developers Computer Systems Odessa iGrafx Evolus yworks By Types: Cloud-based On-premises By Applications: Small and Medium Enterprises (SMEs) Large Enterprises Key Indicators Analysed Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market''s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
   Evolus Appoints Dan Stewart as Vice President and General Manager, International  2021/05/19 00:00:00 BioSpace
Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the appointment of Dan Stewart as Vice President and General Manager of the companys International business.
   Evolus: Q1 Earnings Have Forced A Bottom  2021/05/17 05:32:51 Seeking Alpha
   Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics?  2021/05/13 13:31:00 PR Newswire
NEW YORK, May 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HRTX, CSPR, EOLS, XERS, and ATRA. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.
   Evolus, Inc. (EOLS) CEO David Moatazedi on Q1 2021 Results - Earnings Call Transcript  2021/05/13 02:44:03 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エボラス EOLS Evolus Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)